Automate Your Wheel Strategy on JNJ
With Tiblio's Option Bot, you can configure your own wheel strategy including JNJ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol JNJ
- Rev/Share 37.4631
- Book/Share 32.4389
- PB 5.4734
- Debt/Equity 0.6469
- CurrentRatio 1.0059
- ROIC 0.1216
- MktCap 427600767000.0
- FreeCF/Share 6.7781
- PFCF 26.078
- PE 18.9538
- Debt/Assets 0.2625
- DivYield 0.0286
- ROE 0.3039
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | JNJ | Erste Group | Hold | Buy | -- | -- | July 23, 2025 |
| Downgrade | JNJ | Leerink Partners | Outperform | Market Perform | -- | $153 | May 13, 2025 |
| Resumed | JNJ | BofA Securities | -- | Neutral | -- | $166 | Dec. 10, 2024 |
News
One Sector Paying Big Dividends Is Off to the Best Start in 25 Years Despite Tariffs
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
Investors love dividend stocks, especially the high-yield variety, because they offer a significant income stream and have massive total return potential.
Read More
3 High-Yield Dividend All-Stars to Buy Right Now
Published: April 17, 2025 by: 24/7 Wall Street
Sentiment: Positive
The good news for investors seeking high-yield dividend stocks to buy right now is that there are a number of top options for investors to consider in the high-yield dividend world.
Read More
Here's How You Should Play JNJ Stock After Q1 Earnings Beat
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Neutral
Those who own JNJ stock may stay invested for some time to see how the company achieves growth in 2025 amid the various challenges.
Read More
ETFs in Focus Post JNJ's Q1 Earnings Beat, Dividend Hike
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Johnson & Johnson reports strong first-quarter 2025 results, raises revenue guidance and boosts its quarterly dividends.
Read More
Two New Dividend Picks To Help You Navigate Tariffs And Uncertainty -- One Yields 7%+
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
The acquisitions of Alexandria Real Estate and Unilever enhance sector and geographical diversification, increase dividend income capacity, and reduce portfolio volatility, aligning with The Dividend Income Accelerator Portfolio's goals. Alexandria Real Estate offers a strong Dividend Yield [FWD] of 7.16%, robust financials, and is undervalued, making it a strategic addition to our portfolio. Unilever's fair Valuation and low 24M Beta Factor of 0.11 further reduce portfolio volatility and enhance risk-adjusted returns.
Read More
Johnson & Johnson (JNJ) Q1 2025 Earnings Call Transcript
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Johnson & Johnson (NYSE:JNJ ) Q1 2025 Earnings Conference Call April 15, 2025 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chairman and Chief Executive Officer John Reed - EVP, Innovative Medicine, R&D Joseph Wolk - EVP, Chief Financial Officer Jennifer Taubert - EVP, Worldwide Chairman, Innovative Medicine Tim Schmid - EVP, Worldwide Chairman, MedTech Conference Call Participants Lawrence Biegelsen - Wells Fargo Chris Schott - JPMorgan Asad Haider - Goldman Sachs Danielle Antalffy - UBS Terence Flynn - Morgan Stanley Joanne Wuensch - Citibank Vamil Divan - Guggenheim Securities Matt Miksic - …
Read More
JNJ Tops Q1 Earnings, Ups '25 Sales View to Include Intra-Cellular Deal
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
J&J beats first-quarter earnings and sales estimates. It raises sales guidance for 2025 to reflect the addition of Caplyta from the Intra-Cellular acquisition.
Read More
Import Prices Turn Negative for First Time Since September
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Negative
New economic data is out this morning, some of it reflecting conditions prior to our current tariff realities. We also see Q1 earnings results continue to ramp up, but we won't have the spigots open completely til next week.
Read More
Import Prices, Empire State Come In Mild; Q1 Earnings Beats Abound
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Pre-markets are down somewhat, following yesterday's +3/4-percent gain on the Dow and the S&P 500, +2/3-percent gain for the Nasdaq.
Read More
J&J Expects Tariffs to Cost Company $400 Million
Published: April 15, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
Johnson & Johnson is holding its earnings outlook steady despite President Donald Trump signaling he could put tariffs on the pharmaceutical industry. The administration announced earlier it would conduct an investigation into drug imports.
Read More
Johnson & Johnson beats on top and bottom lines
Published: April 15, 2025 by: CNBC Television
Sentiment: Positive
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss J&J's most recent earnings report.
Read More
Johnson & Johnson: First Look At Q1 Earnings - Solid Quarter Will Calm Nerves
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson's Q1 2025 earnings show a 2.4% sales increase and a significant EPS rise, despite litigation charges impacting GAAP figures. The MedTech division grew 4.1%, driven by acquisitions, while Pharmaceuticals saw a 4.2% increase, despite challenges like Stelara's patent expiry. JNJ raised its full-year revenue guidance and increased its dividend, reflecting confidence in long-term growth despite short-term litigation and tariff uncertainties.
Read More
Johnson & Johnson tops Q1 expectations, lifts 2025 sales outlook
Published: April 15, 2025 by: Proactive Investors
Sentiment: Positive
Johnson & Johnson (NYSE:JNJ) reported its first quarter earnings, with both revenue and profit beating Wall Street expectations driven by strong sales in its oncology portfolio, especially the multiple myeloma drug Darzalex. Revenue was up 2.4% year-over-year at $21.89 billion, ahead of estimates of $21.56 billion.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Johnson & Johnson: Fairly Valued, But Recession-Resilient
Published: April 11, 2025 by: Seeking Alpha
Sentiment: Positive
Johnson & Johnson offers stability and limited downside risk, making it a solid investment in volatile markets, despite not being a high-growth stock. The company's fiscal 2024 results showed moderate growth in sales and earnings, with notable performance in the oncology and cardiovascular segments. Analysts expect low-to-mid single-digit growth for Johnson & Johnson, with a focus on operational efficiency and share buybacks to boost the bottom line.
Read More
Buy, Sell or Hold J&J Stock? Key Tips Ahead of Q1 Earnings
Published: April 11, 2025 by: Zacks Investment Research
Sentiment: Positive
JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Tremfya. We do not expect any improvement in MedTech sales.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
This Johnson & Johnson Analyst Turns Bullish On Shifting Focus From Stelara Concerns To Innovative Medicine
Published: April 09, 2025 by: Benzinga
Sentiment: Positive
While the consensus seems to underappreciate the trajectory of Johnson & Johnson's JNJ Innovative Medicine business, Goldman Sachs says concerns around the Stelara loss of exclusivity appear overdone.
Read More
Pharma tariffs unlikely to hit earnings before 2026, analysts say
Published: April 09, 2025 by: Proactive Investors
Sentiment: Neutral
Potential tariffs on pharmaceuticals under the Trump administration would take more time to have an impact on the sector than investors may realize, analysts at Bank of America believe. US president Donald Trump said on Tuesday that the country would soon be announcing a “major tariff” on pharmaceuticals with the aim of onshoring drug manufacturing.
Read More
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Published: April 09, 2025 by: FXEmpire
Sentiment: Negative
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.
Read More
Big Pharma Stocks Dive Amid Trade War Jitters & Inflation Woes
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Shares of pharma giants like PFE, J&J, AZN, MRK and ABBV decline on investor concerns that retaliatory tariffs could drive up drug prices for U.S. consumers.
Read More
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Published: April 04, 2025 by: Seeking Alpha
Sentiment: Positive
1 Ideal Buy From 23 "Safer" April Dividend Dogs In 50 Fortune World's Most Admired Companies (FWMAC)
Read More
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Both JNJ & PFE expect their sales and profits to improve in 2025.
Read More
Stock Of The Day: Will Johnson & Johnson Rally? The Sell-Off May Have Ended
Published: April 02, 2025 by: Benzinga
Sentiment: Positive
Shares of Johnson & Johnson JNJ are trading higher on Wednesday. Yesterday, they were down more than 7.5%.
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Why Johnson & Johnson Stock Is Sinking Today
Published: April 01, 2025 by: The Motley Fool
Sentiment: Negative
Shares of Johnson & Johnson (JNJ -6.57%) are tumbling on Tuesday. The company's stock lost 6.3% as of 2:25 p.m.
Read More
About Johnson & Johnson (JNJ)
- IPO Date 1943-01-02
- Website https://www.jnj.com
- Industry Drug Manufacturers - General
- CEO Joaquin Duato
- Employees 138100